United Therapeutics UTHR Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.29B-3.5% | $1.33B+5.0% | $1.27B+2.4% | $1.24B+2.6% | $1.21B+1.3% | ||
| $88.4M+3.3% | $85.6M+3.8% | $82.5M+3.5% | $79.7M+3.1% | $77.3M+6.6% | ||
| $149.8M+1.4% | $147.7M+8.8% | $135.7M-1.9% | $138.3M-7.9% | $150.2M+4.3% | ||
| —— | —— | —— | —— | -$48.08M+25.0% | ||
| —— | —— | —— | —— | —— | ||
| $81.5M+54.9% | $52.6M+10.3% | $47.7M+14.9% | $41.5M-15.0% | $48.8M+4.1% | ||
| $87.8M-10.3% | $97.9M— | —— | —— | —— | ||
| $188.4M+133% | $80.9M+283% | -$44.3M-127% | -$19.5M+71.1% | -$67.5M-694% | ||
| —— | —— | —— | —— | —— | ||
| $1.56B+0.1% | $1.56B+0.3% | $1.56B+13.5% | $1.37B-2.9% | $1.41B+6.4% | ||
| $546.4M+5.0% | $520.5M+19.8% | $434.3M+44.6% | $300.3M+6.0% | $283.2M+14.9% | ||
| $3.41B+0.3% | $3.41B+1.2% | $3.36B-0.6% | $3.39B+87.1% | $1.81B+9.9% | ||
| $3.17B+70.3% | $1.86B— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $2.5B+150% | $1B— | —— | —— | —— | ||
| —— | —— | —— | $700M+75.0% | $400M0.0% | ||
| $225.6M+29.7% | $173.9M+72.9% | $100.6M+8.3% | $92.9M-26.8% | $126.9M-16.8% | ||
| $59.6M+259% | $16.6M+1.8% | $16.3M+0.6% | $16.2M+0.6% | $16.1M+32.0% | ||
| -$2.64B-111% | -$1.25B+5.6% | -$1.32B-207% | -$431.2M-53.7% | -$280.6M+77.6% | ||
| —— | —— | -$213.8M-190% | $237.4M-63.4% | $648.4M+32.5% | ||
| $10M-25.9% | $13.5M-27.8% | $18.7M-29.2% | $26.4M-20.0% | $33M-17.9% | ||
| $314.3M+0.3% | $313.3M-16.1% | $373.6M-15.6% | $442.5M+11.6% | $396.4M-1.0% | ||
| -$8.2M-142% | $19.7M+274% | -$11.3M-98.2% | -$5.7M-159% | $9.7M-60.1% | ||
| —— | —— | $21.5M-36.0% | $33.6M+0.6% | $33.4M+17.2% | ||
| $80M+45.5% | $55M-8.3% | $60M— | —— | —— | ||
| $1.24B-21.6% | $1.58B+0.5% | $1.58B-11.5% | $1.78B+6.4% | $1.67B+8.9% | ||
| $3.17B+70.3% | $1.86B— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $168.7M+45.1% | $116.3M— | —— | —— | —— | ||
| $314.3M+0.3% | $313.3M-16.1% | $373.6M-15.6% | $442.5M+11.6% | $396.4M-1.0% | ||
| —— | —— | —— | —— | —— | ||
| $1.02B-2.3% | $1.04B-7.2% | $1.12B+4.8% | $1.07B-5.1% | $1.13B+4.4% | ||
| $1.02B-2.3% | $1.04B-7.2% | $1.12B+4.8% | $1.07B-5.1% | $1.13B+4.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does United Therapeutics generate?
- United Therapeutics (UTHR) generated $1.6B in operating cash flow over the trailing twelve months.
- What is United Therapeutics's free cash flow?
- After $546.4M of capital expenditures, United Therapeutics's free cash flow was $1.0B over the trailing twelve months, down 9.9% year over year.
- Where does United Therapeutics's cash flow data come from?
- Every line is extracted from United Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
